cordialement Sophie B
Roche announced today positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity
You could lose: Starting weight: 200lbs Explore medically guided Weight Loss options based on medical history, goals, and clinical evaluation Compounded Tirzepatide $169.00 / month Compounded Semaglutide $129.00 / month Megaburn (MIC+B12) $79.99 / month A healthcare provider may prescribe a compounded drug if determined that it is medically appropriate
A follow-up trial found that one year after the withdrawal of semaglutide injections, participants had regained two-thirds of their lost weight
Therefore, Studies related to the anti-fibrotic effects of SalB published in the last 23 years were identified through major scientific databases (PubMed, Web of Science, Embase, Google Scholar)
Future trials and research will be required to determine whether any findings derived from the FLOW study could benefit a CKD population beyond those studied in the trial, Giullian said
